Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAPItello-291: capivasertib plus fulvestrant versus placebo plus fulvestrant in HR-positive/HER2-negative advanced breast cancer after aromatase inhibitor progression
CTR20211545Phase 3Active
- Sponsor
- AstraZeneca
- Start
- Aug 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of capivasertib, fulvestrant in breast cancer, sponsored by AstraZeneca. Started Aug 2021; status: active.
02
Drugs
capivasertibfulvestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on CTR20211545.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20211545.